Manufacturers report positive results for use of evolocumab in HIV with high LDL cholesterol
In the BEIJERINCK phase 3B study (n=461), evolocumab reduced the LDL-C by 56.9% vs placebo, with 71.9% achieving at least a 50% reduction. Manufacturers report no new safety concerns in this population.
Source:
Biospace Inc.